A randomized, open-label, international, multi-center, Phase 2 study of Bortezomib Subcutaneous versus Intravenous administration in combination with cyclophosphamide and dexamethasone regimen in newly diagnosed patients with Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2016
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 24 Feb 2016 Status changed from not yet recruiting to recruiting.
- 12 Aug 2013 New trial record